Neurology biomarker · 6 min read
Parkinson’s alpha-synuclein seed amplification, the CSF / skin biomarker for early Parkinson’s disease and Lewy body disorders.
Alpha-synuclein seed amplification assay (α-syn SAA) detects misfolded α-synuclein in CSF or skin biopsy — the emerging biomarker for Parkinson’s disease, dementia with Lewy bodies and REM sleep behaviour disorder, before motor symptoms are evident.
Why patients choose us
- 01
The right hands
We route you to a consultant neurologist experienced in movement disorders and α-synuclein biomarker interpretation.
- 02
Emerging biomarker, expert reading
α-syn SAA is a young test — who interprets the result, alongside your clinical picture, is what makes it useful.
- 03
Independent, and free
We are paid by no clinic, so the recommendation is impartial and costs you nothing.
Key facts
The α-syn SAA test at a glance.
A young biomarker, but a genuine one — the first laboratory test that can biologically identify synucleinopathies during life.
-
Definition
α-synuclein seed amplification assay (α-syn SAA) in CSF or skin biopsy.
-
What it detects
Misfolded α-synuclein aggregates — the pathological hallmark of synucleinopathies.
-
Positive in
Parkinson’s disease, dementia with Lewy bodies, isolated REM sleep behaviour disorder, MSA.
-
Accuracy
Very high sensitivity and specificity in published cohorts.
-
Research role
Guides early neuroprotective trial recruitment and cohort stratification.
-
Complementary tests
Complements DaTscan and structured clinical assessment.
The problem
Parkinson’s has, until recently, had no biological test.
Diagnosis has depended on clinical judgement and imaging — sometimes right for years, sometimes not. α-syn SAA is the first biomarker that identifies the disease process itself, and it changes what a specialist visit can conclude.
-
Early or atypical parkinsonism?
SAA can support or reshape the working diagnosis when the clinical picture is uncertain.
-
Dementia with a Lewy overlap?
Positive SAA in a memory presentation shifts management toward a DLB framework.
-
RBD or prodromal features?
A positive SAA in high-risk phenotypes opens the door to disease-modifying trials.
How it works
From neurology consult to management plan — what happens, in order.
One neurologist from first consult to result — with a clear plan at the end.
Phase 1 · Before
Clinical assessment
Phase 2 · Sampling
Day-case CSF or skin biopsy
Phase 3 · After
Result, follow-up and plan
- 01
Before
Neurology consultation
A consultant movement-disorder neurologist takes a full history and examination — motor and non-motor.
- 02
Before
Confirm clinical suspicion
Motor features (bradykinesia, rigidity, tremor) and non-motor red flags (RBD, hyposmia, autonomic) shape whether SAA is the right test.
- 03
Sampling
CSF sampling or skin biopsy
Lumbar puncture for CSF, or a small punch biopsy of skin from the neck / thigh. Day-case, local anaesthetic.
- 04
Sampling
Sample sent for α-syn SAA
The sample is dispatched to a validated seed-amplification laboratory.
- 05
After
Result in 4–8 weeks
Turnaround is longer than routine bloods — the assay itself takes days to run in duplicate.
- 06
After
Neurology follow-up
Your neurologist reviews the result in the context of your clinical picture and other tests (DaTscan, MRI).
- 07
After
Structured management plan
Dopaminergic therapy, symptomatic management, cognitive support, and — where appropriate — trial referral.
Typical end-to-end: 6–10 weeks. Sampling itself: day-case.
What it shows
When α-syn SAA is the right test.
α-syn SAA answers one biological question — is a synucleinopathy present. These are the presentations where the answer changes the plan.
-
Parkinson’s disease
Positive in the vast majority of clinically diagnosed Parkinson’s patients.
-
Dementia with Lewy bodies
Positive in DLB — helpful when the phenotype overlaps with Alzheimer-type dementia.
-
Isolated REM sleep behaviour disorder
Positive years before motor symptoms — a window into prodromal disease.
-
Multiple system atrophy
Positive in MSA, though with a distinct assay signature in some protocols.
-
Prodromal synucleinopathy
Supports early identification in high-risk phenotypes (RBD, hyposmia, autonomic).
-
Baseline for progression tracking
A biological marker to anchor future longitudinal assessment.
-
Trial recruitment eligibility
Increasingly a gatekeeper for enrolment into disease-modifying trials.
-
Red flag: rapid neurological decline + SAA positive — urgent neurology
Rapidly progressive parkinsonism warrants urgent, not routine, neurology review.
Treatment options
What follows a synucleinopathy diagnosis.
Management is symptomatic today — but the treatment landscape is changing, and SAA is central to trial eligibility.
-
Dopaminergic therapy
Levodopa-based regimens remain the cornerstone of motor symptom control.
-
Rasagiline / selegiline
MAO-B inhibitors used as monotherapy in early disease or as adjuncts later.
-
Deep brain stimulation
For advanced disease with motor fluctuations or refractory tremor — selected patients.
-
Symptomatic RBD treatment
Melatonin or clonazepam for REM sleep behaviour disorder, with safety-planning of the bedroom.
-
Cognitive rehabilitation
Structured cognitive support for those with early cognitive change or DLB overlap.
-
Physiotherapy / SLT
Movement, gait, balance and speech therapy — evidence-based across the disease course.
-
Neuroprotective clinical trials
SAA-positive patients are increasingly eligible for disease-modifying trials.
-
Structured neurology follow-up
Regular review to titrate therapy, screen for non-motor complications, and coordinate care.
Differential and red flags
Not every parkinsonian syndrome is Parkinson’s disease.
The neurologist actively distinguishes idiopathic Parkinson’s from these alternatives — some are urgent, some change management substantially.
What we actively rule out
The nine parkinsonian syndromes to consider.
-
Rapidly progressive parkinsonism
-
Multiple system atrophy (poor prognosis)
-
Dementia with Lewy bodies
-
Autonomic failure
-
Post-encephalitic parkinsonism
-
Drug-induced parkinsonism
-
Vascular parkinsonism
-
Progressive supranuclear palsy
-
Autoimmune movement disorder
Safety and eligibility
A safe test, with a small procedural footprint.
The sampling is well established. The practical points are how a positive or negative result is interpreted, and how it fits into the rest of your care.
-
CSF sampling by lumbar puncture
Performed under local anaesthetic in a day-case setting by an experienced clinician.
-
Skin biopsy alternative
A small punch biopsy (neck / thigh) is an option where lumbar puncture is contraindicated or declined.
-
Post-LP headache
The main risk is a post-dural-puncture headache — usually self-limiting, occasionally needing a blood patch.
-
Bleeding risk
Anticoagulation must be reviewed and, where safe, temporarily adjusted before the procedure.
-
Turnaround is 4–8 weeks
Unlike routine bloods, the assay requires days of amplification and validation.
-
A positive result is not a diagnosis on its own
The neurologist interprets it alongside your clinical picture, imaging and history.
-
A negative result does not fully exclude disease
Assay sensitivity is very high but not 100% — repeat testing may be considered.
-
Result is not directly actionable in isolation
It shapes prognosis and trial eligibility more than day-to-day treatment choices today.
-
Bring prior imaging and letters
DaTscan, MRI and prior neurology letters materially sharpen the interpretation.
Reading your report
A biomarker report can look technical. Its structure isn’t.
Whatever the result, the report keeps to the same four parts.
A quiet reminder
The report is written for your neurologist, not for you — and that’s normal.
If you would like us to talk you through it before your follow-up, just ask.
- 01 Header
Indication and clinical context
Your details, referring question, clinical phenotype and non-motor features.
- 02 Technique
Sample and assay method
CSF or skin biopsy, laboratory used, assay protocol and internal controls.
- 03 Findings
Seed amplification result
Positive / negative, with kinetic parameters and confidence categorisation.
- 04 Impression
The conclusion: read this first
Synucleinopathy consistent / not consistent, with the concrete next step — read this first.
Recognised by major UK insurers
Cover depends on your policy and clinic; we confirm with your insurer before booking.
Frequently asked
Everything we get asked about α-syn SAA.
Quick answers on what the assay does, who should have it, CSF vs skin biopsy, and what a result really means.
-
What is an α-synuclein seed amplification assay?
It is a laboratory technique that detects tiny amounts of misfolded α-synuclein — the protein that clumps together in Parkinson’s disease and other Lewy body disorders — by amplifying it in a test tube until it can be measured. It is the first biological test that reliably identifies synucleinopathies during life.
-
Who should consider α-syn SAA testing?
People with early or atypical parkinsonism, those with dementia where DLB is being considered, patients with confirmed isolated REM sleep behaviour disorder, and — increasingly — those being screened for disease-modifying trials. The decision belongs with a consultant neurologist.
-
CSF or skin biopsy — which is better?
CSF (via lumbar puncture) remains the most validated sample. Skin biopsy is a reasonable alternative when lumbar puncture is contraindicated, declined, or difficult. Both are used in specialist centres.
-
Does a positive result mean I have Parkinson’s?
A positive α-syn SAA means a synucleinopathy is biologically present. Which one — Parkinson’s, DLB, MSA, or prodromal disease — is determined by the clinical picture, imaging and time. Your neurologist puts the pieces together.
-
Can this test predict Parkinson’s before symptoms?
In high-risk groups (particularly people with isolated RBD), SAA can be positive years before motor symptoms appear. This is why it is central to prodromal research and trial recruitment — but preventative treatment is not yet available.
-
How quickly will I get results?
The assay itself takes several days and is typically run in duplicate. Real-world turnaround, including transport and reporting, is usually 4–8 weeks.
Sources
Guidelines and clinical resources.
- NICE. Parkinson’s disease in adults (NG71).
- International Parkinson and Movement Disorder Society.
- Michael J. Fox Foundation for Parkinson’s Research.
- European Federation of Neurological Societies.
Last reviewed 2026-07-30. Next review 2027-07-30. Reviewed by Pulse Atlas Editorial Board, .
Related tests
Looking for a different test?
-
Amyloid scan
PET-based imaging of Alzheimer-type amyloid pathology.
Learn more -
Brain MRI
Structural imaging of the brain — the neurology workhorse.
Learn more -
Central motor conduction
Electrophysiological assessment of the central motor pathways.
Learn more -
All tests
Browse every test and procedure we arrange.
Learn more -
Migraine
Related condition guide.
Learn more -
Multiple Sclerosis
Related condition guide.
Learn more -
Cognitive Behaviour Therapy
Related treatment option.
Learn more -
Craniotomy
Related treatment option.
Learn more
In practice, in London
Why private parkinsons testing alpha synuclein seed amplification moves differently in London
With parkinsons testing alpha synuclein seed amplification, the London question is usually about report turnaround and the radiologist reading it — not whether the scan is available. The wait for parkinsons testing alpha synuclein seed amplification on the NHS depends heavily on where you live and how urgently the referral is graded. Central and West London private clinics can normally book within a week, with imaging or a procedure slot to follow shortly after. It’s worth being honest about the reason for going private: usually it’s time, not a fundamentally different test.
A private parkinsons testing alpha synuclein seed amplification pathway in London usually looks like this: an initial consultation, any diagnostics booked at a nearby facility (most within Zone 1 or 2), and a written report sent to you and your GP within a few days. The consultants we work with hold NHS posts alongside their private lists, which keeps the standards consistent across both settings. For parkinsons testing alpha synuclein seed amplification specifically, the difference between a routine report and a sub-speciality read is where private care earns its keep.
There are a lot of consultants in London who can technically handle parkinsons testing alpha synuclein seed amplification. Fewer who do it week in, week out for the exact question you’re bringing. We spend most of our time working out which is which — and being straight when a different test or a different specialist would serve you better. Everything runs to CQC, GMC and Royal College standards; the choice is about fit, not floor.